中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 36 Issue 6
Jun.  2020
Turn off MathJax
Article Contents

A case of recurrent hilar cholangiocarcinoma in the elderly treated with anlotinib

DOI: 10.3969/j.issn.1001-5256.2020.06.032
Research funding:

 

  • Published Date: 2020-06-20
  • loading
  • [1] XIE C,WAN X,QUAN H,et al. Preclinical characterization of anlotinib,a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor[J]. Cancer Sci,2018,109(4):1207-1219.
    [2] HAN B,LI K,WANG Q,et al. Effect of Anlotinib as a thirdline or further treatment on overall survival of patients with advanced non-small cell lung cancer:The ALTER 0303 phase 3randomized clinical trial[J]. JAMA Oncol,2018,4(11):1569-1575.
    [3] WANG G,SUN M,JIANG Y,et al. Anlotinib,a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcoma[J]. Int J Cancer,2019,145(4):979-993.
    [4] SUN YK,DU F,GAO M. Anlotinib for the treatment of patients with locally advanced or metastatic medullary thyroid cancer[J]. Thyroid,2018,28(11):1455-1461.
    [5] ZHONG CC,CHEN F,YANG JL,et al. Pharmacokinetics and disposition of anlotinib,an oral tyrosine kinase inhibitor,in experimental animal species[J]. Acta Pharmacol Sin,2018,39(6):1048-1063.
    [6] YIN XY. Controversy and strategy of preoperative biliary drainage reducing jaundice in hilar cholangiocarcinoma[J]. Chin J Dig Surg,2018,17(3):229-232.(in Chinese)殷晓煜.肝门部胆管癌术前行胆道引流术减轻黄疸的争议与策略[J].中华消化外科杂志,2018,17(3):229-232.
    [7] VALERO V,COSGROVE D,HERMAN JM,et al. Management of perihilar cholangiocareinoma in the era of multimodal therapy[J]. Expert Rev Gastroenterel Hepatol,2012,6(4):481-495.
    [8] MURAKAMI Y,UEMURA K,SUDO T,et al. Perineural invasion in extrahepatic cholangiocarcinoma:Prognostic impact and treatment strategies[J]. J Gastrointest Surg,2013,17(8):1429-1439.
    [9] CHEN XP,XIANG S. Therapy of hilar cholangiocarcinoma in the precise medicine period[J]. Chin J Dig Surg,2018,17(1):3-8.(in Chinese)陈孝平,项帅.精准医学时代肝门部胆管癌的治疗[J].中华消化外科杂志,2018,17(1):3-8.
    [10] YANG B,XIE H,WANG CP,et al. Study on inhibition of arotinib on human intrahepatic cholangiocarcinoma cell line HCCC-9810[J]. Chin J Med Guide,2017,19(12):1389-1391.(in Chinese)杨斌,谢辉,王春平,等.安罗替尼对人肝内胆管细胞癌细胞系HCCC-9810作用研究[J].中国医药导刊,2017,19(12):1389-1391.
    [11] ZHANG A,LIU B,XU D,et al. Advanced intrahepatic cholangiocarcinoma treated using anlotinib and microwave ablation:A case report[J]. Medicine(Baltimore),2019,98(52):e18435.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (867) PDF downloads(121) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return